G

Genematrix Inc
KOSDAQ:109820

Watchlist Manager
Genematrix Inc
KOSDAQ:109820
Watchlist
Price: 2 500 KRW 1.21% Market Closed
Market Cap: 51B KRW

Net Margin
Genematrix Inc

-16.5%
Current
-32%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-16.5%
=
Net Income
-1.7B
/
Revenue
10.4B

Net Margin Across Competitors

No Stocks Found

Genematrix Inc
Glance View

Market Cap
49.9B KRW
Industry
Biotechnology

GENEMATRIX, Inc. engages in the development of platform and molecular diagnostics products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 60 full-time employees. The company went IPO on 2009-11-06. The firm operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.

Intrinsic Value
1 838 KRW
Overvaluation 26%
Intrinsic Value
Price
G
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-16.5%
=
Net Income
-1.7B
/
Revenue
10.4B
What is the Net Margin of Genematrix Inc?

Based on Genematrix Inc's most recent financial statements, the company has Net Margin of -16.5%.

Back to Top